Copies of nonbiological complex drugs: generic, hybrid or biosimilar?

DOI: 10.1016/j.drudis.2018.08.003
Drug Discovery Today, 2019, 24, 250-255.

#	Paper	IF	Citations
12	Glatiramer acetate: A complex drug beyond biologics. *European Journal of Pharmaceutical Sciences*, **2019**, 133, 8-14	5.1	3
11	Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies. *Drug Discovery Today*, **2020**, 25, 321-329	8.8	5
10	Old active ingredients in new medicinal products: is the regulatory path coherent with patientsU expectations?. *Drug Discovery Today*, **2020**, 25, 1337-1347	8.8	3
9	Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System. *AAPS PharmSciTech*, **2020**, 21, 65	3.9	3
8	Tackling the challenges of nanomedicines: are we ready?. *American Journal of Health-System Pharmacy*, **2021**, 78, 1047-1056	2.2	1
7	How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries. *Pharmaceutics*, **2021**, 13,	6.4	
6	A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. *Annals of the New York Academy of Sciences*, **2021**, 1502, 5-13	6.5	1
5	Design and development of topical liposomal formulations in a regulatory perspective. *Drug Delivery and Translational Research*, **2021**, 1	6.2	1
4	A quality by design (QbD) approach in pharmaceutical development of lipid-based nanosystems: A systematic review. *Journal of Drug Delivery Science and Technology*, **2022**, 70, 103207	4.5	1
3	Regulatory Science Approach in Pharmaceutical Development of Follow-On Versions of Non-Biological Complex Drug Products. *Journal of Pharmaceutical Sciences*, **2022**,	3.9	0
2	Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation. **2022**, 178, 1-24		0
1	The anatomical therapeutic chemical classification is flexible enough to describe the innovation in biotechnological drugs?.		0